Impact of dietary vitamin D on initiation and progression of oral cancer.

Aparajita Verma, Vui King Vincent-Chong, Hendrik DeJong, Pamela A Hershberger, Mukund Seshadri
Author Information
  1. Aparajita Verma: Center for Oral Oncology, United States.
  2. Vui King Vincent-Chong: Center for Oral Oncology, United States.
  3. Hendrik DeJong: Center for Oral Oncology, United States.
  4. Pamela A Hershberger: Department of Pharmacology and Therapeutics, United States.
  5. Mukund Seshadri: Center for Oral Oncology, United States; Department of Dentistry and Maxillofacial Prosthetics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, United States. Electronic address: Mukund.Seshadri@roswellpark.org.

Abstract

Calcitriol, the active metabolite of vitamin D, has been widely studied for its preventive and therapeutic activity against several cancers including oral squamous cell carcinoma (OSCC). However, the impact of dietary vitamin D supplementation on initiation and progression of OSCC is unclear. To address this gap in knowledge, we conducted preclinical trials using the 4-nitroquinoline-1-oxide 4NQO carcinogen model of oral carcinogenesis. Female C57BL/6 mice were maintained on one of three vitamin D diets [25 IU, 100 IU, 10,000 IU] and exposed to 4NQO in drinking water for 16 weeks followed by regular water for 10 weeks. Body weight measurements obtained through the study duration did not reveal any differences between the three diets. Animals on 100 IU diet showed lower incidence of high-grade dysplasia/OSCC and higher CD3 + T cells compared to animals on 25 IU and 10,000 IU diets. Serum 25OHD levels were highest in animals on 10,000 IU diet at week 0 prior to carcinogen exposure but showed ∼50 % reduction at week 26. Histologic evaluation revealed highest incidence of OSCC in animals maintained on 10,000 IU diet. Animals on 100 IU and 10,000 IU diets showed higher vitamin D receptor VDR and CYP24A1 immunostaining in high-grade dysplastic lesions and OSCC compared to normal tongue. Validation studies performed in a 4NQO-derived OSCC model showed that short-term treatment of animals on a 25 IU diet with calcitriol significantly inhibited tumor growth compared to controls but did not affect tumor growth in animals on reference diet 1000 IU. Collectively, our results highlight the complex dynamics between vitamin D status and oral carcinogenesis. Our observations also suggest that therapeutic benefits of short-term calcitriol treatment may be more pronounced in vitamin D deficient hosts.

Keywords

References

  1. Neoplasia. 2019 Apr;21(4):376-388 [PMID: 30875566]
  2. Cancer Prev Res (Phila). 2019 Jun;12(6):343-356 [PMID: 31028080]
  3. J Nutr. 2008 Jun;138(6):1114-20 [PMID: 18492843]
  4. J Diet Suppl. 2014 Jun;11(2):145-54 [PMID: 24670118]
  5. Contemp Oncol (Pozn). 2017;21(2):145-151 [PMID: 28947884]
  6. J Oncol. 2011;2011:603740 [PMID: 21772845]
  7. J Natl Cancer Inst. 2001 May 16;93(10):745-53 [PMID: 11353784]
  8. Basic Life Sci. 1975;5B:763-71 [PMID: 811213]
  9. Anticancer Res. 2015 Jan;35(1):311-7 [PMID: 25550565]
  10. EBioMedicine. 2016 Jan 09;4:138-45 [PMID: 26981578]
  11. Oral Oncol. 2009 Apr-May;45(4-5):361-85 [PMID: 18849188]
  12. N Engl J Med. 2006 Feb 16;354(7):684-96 [PMID: 16481636]
  13. Cancer Prev Res (Phila). 2015 Oct;8(10):895-904 [PMID: 26276745]
  14. Oral Oncol. 2009 Apr-May;45(4-5):309-16 [PMID: 18804401]
  15. Cell. 2011 Mar 4;144(5):646-74 [PMID: 21376230]
  16. Mund Kiefer Gesichtschir. 2006 Mar;10(2):89-93 [PMID: 16485137]
  17. Hum Immunol. 2010 Jul;71(7):659-65 [PMID: 20438786]
  18. Head Neck Oncol. 2011 Jan 06;3:2 [PMID: 21211041]
  19. Cytokine. 2012 Jun;58(3):448-54 [PMID: 22450225]
  20. Cancer Prev Res (Phila). 2010 Nov;3(11):1493-502 [PMID: 20978113]
  21. Cancer. 1992 Jul 1;70(1):14-9 [PMID: 1606536]
  22. Front Immunol. 2019 Jun 06;10:1307 [PMID: 31244851]
  23. J Endocrinol. 2000 Apr;165(1):163-72 [PMID: 10750047]
  24. Nutr Cancer. 2018 Apr;70(3):413-417 [PMID: 29533115]
  25. Arch Otolaryngol Head Neck Surg. 2007 Nov;133(11):1149-52 [PMID: 18025321]
  26. Cancer Prev Res (Phila). 2015 Sep;8(9):765-76 [PMID: 26100522]
  27. Oral Oncol. 2006 Aug;42(7):655-67 [PMID: 16448841]
  28. Med Oral Patol Oral Cir Bucal. 2015 Mar 01;20(2):e188-95 [PMID: 25662556]
  29. Drug Des Devel Ther. 2016 Jun 17;10:1995-2002 [PMID: 27382252]
  30. Nat Rev Cancer. 2007 Sep;7(9):684-700 [PMID: 17721433]
  31. Head Neck. 2016 Apr;38 Suppl 1:E459-67 [PMID: 25677579]
  32. Cancer Epidemiol Biomarkers Prev. 2009 Dec;18(12):3368-74 [PMID: 19959684]
  33. J Oral Pathol Med. 2018 May;47(5):484-491 [PMID: 29573032]
  34. Endocrinology. 2012 Jun;153(6):2576-87 [PMID: 22454149]
  35. Cancer Chemother Pharmacol. 2006 Jan;57(2):234-40 [PMID: 16180015]
  36. Exp Ther Med. 2011 Mar;2(2):181-193 [PMID: 22977487]
  37. Sci Rep. 2016 Nov 04;6:36017 [PMID: 27812016]
  38. Mol Med Rep. 2017 Jan;15(1):467-473 [PMID: 27922682]
  39. Calcif Tissue Int. 2013 Feb;92(2):163-76 [PMID: 23001438]
  40. CA Cancer J Clin. 2015 Mar;65(2):87-108 [PMID: 25651787]
  41. Cancers (Basel). 2013 Aug 14;5(3):1072-85 [PMID: 24202334]
  42. Mol Cancer Ther. 2015 Jun;14(6):1365-75 [PMID: 25824337]
  43. Head Neck. 2012 Oct;34(10):1450-5 [PMID: 22287291]
  44. Oncoimmunology. 2018 Jul 23;7(9):e1476817 [PMID: 30228945]
  45. N Engl J Med. 2019 Jan 3;380(1):33-44 [PMID: 30415629]

Grants

  1. P30 CA016056/NCI NIH HHS
  2. R01 CA204636/NCI NIH HHS
  3. R01 DE024595/NIDCR NIH HHS

MeSH Term

4-Nitroquinoline-1-oxide
Animals
Body Weight
Calcitriol
Carcinogenesis
Carcinoma, Squamous Cell
Dietary Supplements
Disease Models, Animal
Disease Progression
Humans
Mice
Mouth Neoplasms
Receptors, Calcitriol
Vitamin D
Vitamin D Deficiency
Vitamin D3 24-Hydroxylase

Chemicals

Receptors, Calcitriol
Vdr protein, mouse
Vitamin D
4-Nitroquinoline-1-oxide
Vitamin D3 24-Hydroxylase
Calcitriol

Word Cloud

Created with Highcharts 10.0.0IUDvitamin10OSCC000dietanimalsoraldietsshowedcarcinogenesis100comparedtherapeuticcellcarcinomadietaryinitiationprogression4NQOcarcinogenmodelmaintainedthreewaterweeksAnimalsincidencehigh-gradehigherTcells25highestweekVDRshort-termtreatmentcalcitrioltumorgrowthCalcitriolactivemetabolitewidelystudiedpreventiveactivityseveralcancersincludingsquamousHoweverimpactsupplementationunclearaddressgapknowledgeconductedpreclinicaltrialsusing4-nitroquinoline-1-oxideFemaleC57BL/6miceone[25IU]exposeddrinking16followedregularBodyweightmeasurementsobtainedstudydurationrevealdifferenceslowerdysplasia/OSCCCD3+Serum25OHDlevels0priorexposure∼50%reduction26HistologicevaluationrevealedreceptorCYP24A1immunostainingdysplasticlesionsnormaltongueValidationstudiesperformed4NQO-derivedsignificantlyinhibitedcontrolsaffectreference1000CollectivelyresultshighlightcomplexdynamicsstatusobservationsalsosuggestbenefitsmaypronounceddeficienthostsImpactcancerDietOralSquamousVitamin

Similar Articles

Cited By